01—Abstract
Summary
Summary of the 10-K/A filed March 27, 2013. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories' 2012 10-K filing reveals a company in the midst of a significant strategic shift with the announced separation of its research-based pharmaceuticals business into a new entity, AbbVie Inc. This separation, completed in early 2013, reshaped Abbott's business segments, with the Proprietary Pharmaceutical Products segment no longer existing post-separation.
The company's diversified portfolio spans pharmaceuticals (prior to separation), diagnostics, nutritionals, and vascular products, each facing distinct competitive landscapes and market dynamics. Financially, Abbott demonstrated resilience, with notable revenue growth driven by its Pharmaceutical and Nutritional segments, supported by strong product performance like HUMIRA and new product introductions. The company also focused on operational efficiencies and margin improvement across its businesses, particularly in Diagnostics and Nutritionals.
However, the report also highlights significant litigation charges, including a substantial settlement related to Depakote sales and marketing practices. The company's financial position remained robust, supported by strong operating cash flows, though debt levels were managed, including early extinguishment of a significant portion of long-term debt in preparation for the AbbVie separation.
02—Key points
Key Highlights
- Abbott Laboratories completed the separation of its research-based pharmaceuticals business into AbbVie Inc. on January 1, 2013, significantly altering its business structure.
- The company reported strong performance in its Nutritional and Diagnostic Products segments, with strategic focus on margin improvement and new product development.
- HUMIRA continued to be a key revenue driver, showing substantial sales growth across multiple indications.
- Abbott faced and resolved significant litigation, including a $1.6 billion settlement related to Depakote sales and marketing practices.
- The company invested heavily in research and development, with $4.3 billion allocated in 2012, focusing on pharmaceutical, medical, and nutritional products.
- Abbott's financial health remained strong, with substantial operating cash flows and a manageable debt profile, further strengthened by debt extinguishment activities.
- The company's Vascular Products segment saw revenue decrease, partly due to the winding down of certain third-party product agreements, but maintained market leadership with its Xience drug-eluting stent franchise.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2012, Abbott Laboratories kept $0.31.
- Revenue$19.05B100.0%
- Cost of revenue−$8.90B46.7%
- Gross profit$10.15B53.3%
- Operating costs−$8.79B46.1%
- Operating income$1.36B7.1%
- Interest, other & tax$4.56B23.9%
- Net income$5.92B31.1%
Where FY2012 revenue went
$19.05B- Cost of revenue: $8.90B, 47% of revenue
- SG&A: $6.74B, 35% of revenue
- Operating income: $1.36B, 7.1% of revenue
- Other operating costs: $2.06B, 11% of revenue
Kept 7.1% as operating incomeOperating income $1.36B · 7.1%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-K/AFY2012filed March 27, 2013Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $19.05B$21.41B | −11.0% |
| Cost of Revenue | $8.90B$10.02B | −11.2% |
| Gross Profit | $10.15B$11.39B | −10.9% |
| SG&A Expenses | $6.74B$7.37B | −8.6% |
| Operating Expenses | $17.69B$19.78B | −10.6% |
| Operating Income | $1.36B$1.63B | −16.5% |
| Interest Expense | $320.00M$359.00M | −10.9% |
| Net Income | $5.92B$4.71B | +25.5% |
| EPS (Basic) | $3.76$3.03 | +24.1% |
| EPS (Diluted) | $3.72$3.01 | +23.6% |
| Shares Outstanding (Basic) | 1.57B1.56B | +1.2% |
| Shares Outstanding (Diluted) | 1.59B1.57B | +1.6% |
05—Questions
Frequently Asked Questions
What was the most significant event affecting Abbott Laboratories during this reporting period?
The most significant event was the planned separation of its research-based pharmaceuticals business into a new, independent public company named AbbVie Inc. This separation was completed on January 1, 2013, which materially changed Abbott's business structure and reporting segments.
How did Abbott Laboratories perform financially in 2012, considering the upcoming separation?
Abbott demonstrated solid financial performance, with overall net sales increasing. Key growth drivers included HUMIRA and its Nutritional Products segment, while the company also focused on improving operating margins in its Diagnostics and Nutritional businesses. Despite significant litigation expenses, the company maintained strong operating cash flows.
What are the main business segments of Abbott Laboratories after the AbbVie separation?
Following the separation, Abbott Laboratories will primarily focus on its diversified medical products businesses, including Diagnostics, Nutritionals, Medical Devices (Vascular and other), and Established Pharmaceuticals (international branded generics). The Proprietary Pharmaceutical Products segment, which was largely the basis for AbbVie, will no longer be part of Abbott.
Were there any major legal or regulatory issues highlighted in the report?
Yes, Abbott disclosed a significant charge of $1.6 billion in 2012 related to the settlement of federal, state, and consumer protection claims concerning the sales and marketing of its Depakote product. The company also discussed ongoing investigations into sales and marketing activities for its biliary and carotid/coronary stents.
06—Continue